IL10RA modulates crizotinib sensitivity in NPM1-ALK(+) anaplastic large cell lymphoma

Anaplastic large cell lymphoma (ALCL) is a T-cell malignancy predominantly driven by a hyperactive anaplastic lymphoma kinase (ALK) fusion protein. ALK inhibitors, such as crizotinib, provide alternatives to standard chemotherapy with reduced toxicity and side effects. Children with lymphomas driven...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Prokoph, Nina, Probst, Nicola A., Lee, Liam C., Monahan, Jack M., Matthews, Jamie D., Liang, Huan-Chang, Bahnsen, Klaas, Montes-Mojarro, Ivonne A., Karaca-Atabay, Elif, Sharma, Geeta G., Malik, Vikas, Larose, Hugo, Forde, Sorcha D., Ducray, Stephen P., Lobello, Cosimo, Wang, Qi, Luan, Shi-Lu, Pospíšilová, Šárka, Gambacorti-Passerini, Carlo, Burke, G. A. Amos, Pervez, Shahid, Attarbaschi, Andishe, Janíková, Andrea, Pacquement, Hélène, Landman-Parker, Judith, Lambilliotte, Anne, Schleiermacher, Gudrun, Klapper, Wolfram, Jauch, Ralf, Woessmann, Wilhelm, Vassal, Gilles, Kenner, Lukas, Merkel, Olaf, Mologni, Luca, Chiarle, Roberto, Brugières, Laurence, Geoerger, Birgit, Barbieri, Isaia, Turner, Suzanne D.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2020
Assuntos:
Lymphoid Neoplasia
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7530646/
https://ncbi.nlm.nih.gov/pubmed/32573700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019003793
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares